GlassScriptPhysician profile
Amanda A Trott Gregorio
NPI 1568653756
$15,864.14
in general payments reported to CMS, 2019-2025
41 companies · $3,618 in 2025
The $3,618 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $928 · 2021: $1,253 · 2022: $2,518 · 2023: $2,774 · 2024: $3,298 · 2025: $3,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,525 · Education: $144 · Consulting Fee: $21.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,524.64 |
| Education | $143.99 |
| Consulting Fee | $21.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,714.87 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,576.79 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,449.76 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Astrazeneca Pharmaceuticals LP | $1,354.84 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,168.56 | 2019-2025 | |
| Genentech USA, INC. | $906.41 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $843.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $822.63 | 2019-2025 | |
| Optinose US, INC. | $788.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $690.35 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Grifols USA, LLC | $566.74 | 2019-2025 | Xembify |
| Kaleo, INC. | $398.07 | 2019-2024 | Auvi-Q |
| Amgen INC. | $349.22 | 2021-2025 | Tezspire |
| Alk-Abello, INC | $331.65 | 2019-2025 | Grastek, Ragwitek, Odactra |
| Octapharma USA, INC. | $310.20 | 2021-2025 | Cutaquig, Panzyga |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Trott Gregorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.